Clinical trial
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot…
NCT00128596 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00128596 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery |
| Official title | A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 25 |
| Start date | Jun 1, 2004 |
| Primary completion | Dec 1, 2005 |
| First posted | Aug 10, 2005 |
| Last update posted | Apr 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: